B. C. G. plus recombinant interferon α2b in superficial bladder cancer

We have studied the efficacy of adjuvant therapy in the form of low dose B.C.G. and interferon alpha 2b. In the present study 7patients with superficial bladder car-cinoma (6 recurrent and I primary) have been treated by TURBT and intravesical instillation of B. C. G. 80 mg plus interferon alpha 2b 10 million units weekly for 8 weeks. All patients accepted the therapy without sig-nificant morbidity and complication. Follow-up,period ranges between 11-16 months and none of the patients have developed recurrence till date. Interferon alpha 2b along with B.C.G. is a good al-ternative agent, for prophylaxis in case of high grade and recurrent bladder tumou